middle.news

Bioxyne Ltd H1 FY26 Revenue Surges 149% on Medicinal Cannabis and Psychedelic Demand

9:58am on Thursday 26th of February, 2026 AEDT Pharmaceuticals
Read Story

Bioxyne Ltd H1 FY26 Revenue Surges 149% on Medicinal Cannabis and Psychedelic Demand

9:58am on Thursday 26th of February, 2026 AEDT
Key Points
  • Revenue jumps 149% to $31.3 million in H1 FY26
  • Net profit after tax rises 126% to $7.3 million
  • Expanded manufacturing capacity and international market entry
  • Dual listing completed on Frankfurt Stock Exchange
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about BIOXYNE (ASX:BXN)
OPEN ARTICLE